Biocon receives Health Canada approval for psoriasis, Crohn's disease treatment autoinjector pen
NiveshIQ
NSE: BIOCON · Pharma
Biocon Ltd.
₹431.10▼ ₹1.35 (-0.31%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on BIOCON. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Biocon Ltd.
Biocon Limited is a leading Indian biotechnology company operating through Generics, Biosimilars, and Research segments. The company offers a diverse portfolio of generic formulations, API products, and biosimilars, including pegfilgrastim, trastuzumab, and adalimumab. Biocon provides integrated discovery, development, and manufacturing services to pharmaceutical and biotechnology companies. The company has recently received EMA approval to supply Semglee insulin to Europe and has strengthened its commitment to diabetes care in Malaysia. Biocon's revenue stood at ₹16,927 Cr, with a net income of ₹386 Cr. The company has a strong presence in the Indian market and is expanding its global footprint. With a focus on biologics and biosimilars, Biocon is well-positioned for growth in the healthc
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹14,756 Cr +32.10% | ₹15,261 Cr +3.40% | ₹16,927 Cr |
| EBITDA Margin | 21.78% | 20.54% | 22.44% |
| Net Profit | ₹1,298 Cr +101.90% | ₹1,429 Cr +10.10% | ₹771.70 Cr |
| EPS | ₹8.52 | ₹8.44 | ₹2.82 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Biocon gets Canadian health regulator's nod for Yesintek autoinjector pen
Biocon gets Canadian health regulator's nod for Yesintek autoinjector pen
🔒
+ 3 more stories about Biocon Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹4, 517 Cr, PAT ₹11 Cr, EPS ₹0.78, EBITDA margin 23.8%. Growth context: revenue YoY +2.3%, PAT YoY -97.6%, revenue QoQ +8.2%, PAT QoQ -121.3%. Street verdict: beat, revenue surprise -0.6%, PAT surprise +16.0%.
Recent corporate activity highlights product launches, approvals, and therapy-mix improvement and order wins, deal pipel...
FY26 (last completed FY): revenue ₹16, 927 Cr, PAT ₹772 Cr, EBITDA margin 22.4%, EPS ₹2.82. Street consensus for FY27e: ...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for BIOCON
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track BIOCON alongside your other holdings
Unlock full BIOCON research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Biocon Ltd.?
NiveshIQ detects active intelligence signals for Biocon Ltd. (BIOCON) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Biocon Ltd.?
Biocon Ltd. operates in the Pharma sector with a market capitalisation of ₹6,132,408.0L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.